10-K: Outlook Therapeutics Faces Second FDA Rejection for Wet AMD Drug

Outlook Therapeutics received a second Complete Response Letter from the FDA for its wet AMD treatment, ONS-5010/LYTENAVA, citing insufficient evidence of effectiveness, despite recent EU and UK market authorizations.

Summary

• ONS-5010/LYTENAVA (bevacizumab-gamma) is the first ophthalmic formulation of bevacizumab approved in the EU (May 2024) and UK (July 2024) for wet age-related macular degeneration (wet AMD).
• The company launched ONS-5010/LYTENAVA directly in Germany and the UK in June 2025, generating $1.4 million in revenue for fiscal year 2025.
• A second Complete Response Letter (CRL) was received from the FDA on August 27, 2025, for the Biologics License Application (BLA) for ONS-5010/LYTENAVA in the United States, citing a lack of substantial evidence of effectiveness.
• The FDA recommended submission of confirmatory efficacy data, while reiterating that the NORSE TWO trial met its primary endpoint for effectiveness.
• The NORSE EIGHT trial, conducted to address FDA requirements, did not meet its pre-specified non-inferiority endpoint at week 8, but demonstrated improvement in vision, biologic activity, and a favorable safety profile at week 12.
• The BLA was resubmitted to the FDA on November 3, 2025, with a Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025.
• Outlook Therapeutics reported a net loss of $62.4 million for the fiscal year ended September 30, 2025, an improvement from $75.4 million in 2024.
• Cash and cash equivalents stood at $8.1 million as of September 30, 2025, with an additional $14.9 million in net proceeds from an at-the-market (ATM) sales program received since that date.
• The company issued a $33.1 million unsecured convertible promissory note to Avondale Capital, LLC in March 2025, maturing July 1, 2026, with quarterly debt reduction obligations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.
• Workforce reductions were implemented in December 2024 (approximately 23% headcount) and September 2025 to reduce operating expenses and preserve capital.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the second FDA Complete Response Letter for the lead product, the failure of a key clinical trial (NORSE EIGHT) to meet its primary endpoint at week 8, and the explicit disclosure of 'substantial doubt about our ability to continue as a going concern.' While there are positives like EU/UK approval and initial revenue, these are overshadowed by the significant regulatory and financial challenges.

Positives

• ONS-5010/LYTENAVA received Marketing Authorization from the European Commission in May 2024 and the MHRA in the UK in July 2024 for wet AMD.
• Generated initial revenue of $1.4 million from sales of LYTENAVA in Germany and the UK during fiscal year 2025.
• The pivotal Phase 3 NORSE TWO clinical trial met its primary and key secondary efficacy endpoints, demonstrating statistically significant and clinically relevant improvements in Best Corrected Visual Acuity (BCVA).
• The NORSE EIGHT trial, despite missing its primary endpoint at week 8, showed improvement in vision, presence of biologic activity, and a continued favorable safety profile for ONS-5010/LYTENAVA at week 12.
• FDA has agreed on Special Protocol Assessments (SPAs) for three additional Phase 3 clinical trials (NORSE FOUR, FIVE, and SIX) for ONS-5010/LYTENAVA to treat BRVO and DME, pending initial FDA approval for wet AMD.
• A strategic collaboration agreement with Cencora is in place to support the global commercial launch of ONS-5010/LYTENAVA, providing comprehensive support in the EU and UK.
• If approved by the FDA, ONS-5010/LYTENAVA is expected to receive 12 years of regulatory exclusivity in the United States.
• Net loss decreased by $12.9 million, from $75.4 million in FY2024 to $62.4 million in FY2025.
• Successfully completed a Warrant Inducement Transaction in January 2025, generating $16.6 million in net proceeds.

Negatives

• Incurred significant losses and negative cash flows from operations since inception, with a net loss of $62.4 million in FY2025.
• There is substantial doubt about the company's ability to continue as a going concern due to insufficient cash resources to fund planned operations for the next 12 months.
• Received a second Complete Response Letter (CRL) from the FDA in August 2025 for the ONS-5010/LYTENAVA BLA, citing a lack of substantial evidence of effectiveness and recommending confirmatory efficacy data.
• The NORSE EIGHT trial did not meet its pre-specified non-inferiority endpoint at week 8 against ranibizumab.
• The company is highly dependent on the success of ONS-5010/LYTENAVA, its only product approved in the EU/UK and only product candidate in active development.
• Workforce reductions in December 2024 (23% headcount) and September 2025 led to severance costs and potential loss of institutional knowledge and expertise.
• Pending securities class action lawsuit and a shareholder derivative action allege violations of securities laws and breach of fiduciary duties, which could result in substantial damages and divert management's time and attention.
• The Syntone Warrant Inducement Transaction, expected to generate approximately $2.4 million in proceeds, is subject to regulatory approval and has not yet closed.
• The March 2025 Note includes provisions for increasing the outstanding balance by 5-10% and accruing interest at 22% per annum upon an Event of Default, and requires cash conversion if the stock price falls below $0.404 per share.

Risks

• Incurred significant losses and negative cash flows from operations since inception and expects to continue for at least the next 12 months.
• Has not generated material revenue from any product sales and may never be profitable.
• Substantial doubt exists about the ability to continue as a going concern, requiring substantial additional funding that may not be available on acceptable terms or at all.
• Failure to obtain necessary capital when needed may force delays, limits, or termination of product development efforts or other operations.
• Raising additional capital, including modifications to existing convertible securities, may cause dilution to securityholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Received a second Complete Response Letter from the FDA in August 2025 for ONS-5010/LYTENAVA for wet AMD in the United States, indicating a lack of substantial evidence of effectiveness and requiring additional well-controlled clinical evidence.
• May need to enter into alliances with other companies for development and commercialization; failure to form or maintain these on favorable terms could harm the business.
• Limited resources and access to capital necessitate prioritizing development of certain product candidates, and these decisions may prove to be wrong.
• Clinical drug development is a lengthy and expensive process, with potential for substantial delays or failure to demonstrate safety and efficacy to regulatory authorities.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization; existing insurance coverage may be insufficient.
• The development and commercialization of pharmaceutical products are subject to extensive regulation, and regulatory approvals for ONS-5010/LYTENAVA outside the EU/UK or for future product candidates may not be obtained timely or at all.
• Any delays in the commencement or completion, or termination or suspension, of planned or future clinical trials could result in increased costs, delay revenue generation, and adversely affect commercial prospects.
• Faces intense competition and rapid technological change; competitors may develop similar, more advanced, or more effective therapies, or gain approval first.
• Currently has no internal marketing and sales organization and relies on third parties for commercialization, which may not generate sufficient revenue.
• Relies on single-source suppliers for clinical trial services, drug substance manufacturing, and fill-finish manufacturing of ONS-5010/LYTENAVA; loss of any supplier could harm the business.
• Risk of infringing or being alleged to infringe intellectual property rights of third parties, which could prevent or delay development and commercialization efforts.
• May become involved in expensive, time-consuming, and potentially unsuccessful lawsuits to protect or enforce future patents.
• Inability to obtain and maintain effective patent rights for ONS-5010/LYTENAVA or other product candidates could prevent competitors from using important technologies.
• Failure to comply with obligations in intellectual property license agreements could lead to loss of important license rights.
• Unfavorable global economic and political conditions (e.g., inflation, interest rates, tariffs, trade tensions, overseas conflict) could adversely affect business, financial condition, or results of operations.
• Highly dependent on key executives and personnel; inability to retain or recruit additional management, clinical, and scientific personnel could harm the business.
• Pending securities class action lawsuit and shareholder derivative action could result in substantial damages, divert management's time, and materially affect results of operations.
• Compromise of information technology systems or data, or those of third parties, could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• The trading price of securities is likely to be volatile, and purchasers could incur substantial losses.
• GMS Ventures and Investments beneficially owns a significant percentage of common stock (41.9% as of September 30, 2025) and can exert significant control over matters subject to stockholder approval.
• Off-label repackaging of Avastin at compounding pharmacies may continue, which could materially adversely affect the business and financial condition.
• The commercial success of any current or future product candidate depends on market acceptance by physicians, patients, third-party payors, and others in the medical community.
• Third-party coverage and reimbursement status of newly approved products is uncertain; failure to obtain or maintain adequate coverage could limit marketability and revenue generation.
• Off-label use or misuse of products may harm reputation, lead to costly product liability suits, and/or subject the company to penalties.
• Affected patient populations for ONS-5010/LYTENAVA or future product candidates may be smaller than projected, impacting addressable markets.
• Delays or unsuccessful launches could lead to costs related to excess inventory or unused manufacturing capacity.
• Disruptions at the FDA and other government agencies caused by shutdowns or funding shortages could hinder timely product development, approval, or commercialization.
• Acquisitions or joint ventures could disrupt business, cause dilution to stockholders, and otherwise harm the business.
• Development of product candidates in combination with other approved therapeutics carries risks if approvals are revoked or safety/efficacy issues arise.
• Employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards.
• Business activities are subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws.
• Subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, and industry standards related to data privacy and security, with potential for significant penalties for non-compliance.
• As a smaller reporting company, the reduced reporting requirements may make investing in securities less attractive.
• Incurs significant costs and demands upon management from complying with laws and regulations affecting public companies in the United States, which may harm operating results.
• Future sales and issuances of common stock or rights to purchase securities could result in additional dilution of percentage ownership and cause the market price of securities to fall.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited by ownership changes under Sections 382 and 383 of the Internal Revenue Code.
• The enactment of proposed or future tax legislation may adversely impact financial condition and results of operations.
• International operations may subject the company to greater than anticipated tax liabilities.
• Does not intend to pay dividends on capital stock; any returns will be limited to the value of securities.
• Provisions in amended and restated certificate of incorporation and bylaws, as well as Delaware law, could make it more difficult or costly for a third party to acquire the company.
• Exclusive forum provision in charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

Outlook Therapeutics aims to launch ONS-5010/LYTENAVA directly in the United States if FDA approval is received, and may seek approval in other international markets. The company plans to develop ONS-5010/LYTENAVA for additional retina diseases like DME and BRVO, with FDA-agreed SPAs for future trials, contingent on initial FDA approval for wet AMD. If approved in the US, ONS-5010/LYTENAVA is expected to receive 12 years of regulatory exclusivity. The company anticipates continued significant expenses and operating losses for at least the next 12 months and plans to finance future operations through a combination of strategic collaborations, equity/debt issuances, and potential future product sales. The majority of cash payments related to the September 2025 workforce reduction are expected to be completed by Q3 2026. The company will continue to evaluate the impact of healthcare reform measures, including the Affordable Care Act and the Inflation Reduction Act, on its business, expecting more rigorous coverage criteria and lower reimbursement. The recently enacted One Big Beautiful Bill Act (OBBBA) is not expected to materially impact the company's financials, but will reinstate R&D expenditure deductions in fiscal 2026 and adjust the FDDEI tax rate in fiscal 2027.

Management Comments

• Our goal is to commercialize ONS-5010/LYTENAVA as the first, and only, approved bevacizumab for ophthalmic use in the EU, UK, United States and other markets.
• We believe ONS-5010/LYTENAVA has potential to mitigate risks associated with off-label use of unapproved bevacizumab.
• We believe there is significant opportunity in Europe with a total anti-VEGF retina market estimated to be approximately $3.6 billion, including approximately 1.52 million treated patients and approximately 8.3 million total anti-VEGF units.
• We similarly see significant opportunity in the United States, with an estimated $8.5 billion total anti-VEGF retina market, where 55% of physicians state off-label repackaged bevacizumab is the preferred first-line product.
• We believe ONS-5010/LYTENAVA has the potential to become the anti-VEGF cornerstone of care for retinal diseases and help lower the aggregate costs of treating retinal diseases for the overall healthcare system in the EU and UK, and also in the United States if the product is approved there.
• Management does not believe that the Company’s existing cash and cash equivalents as of September 30, 2025, together with $14,931,537 in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2025, are sufficient to fund the Company’s operations through one year from the Form 10-K filing date. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

Industry Context

The anti-VEGF retina market is substantial, estimated at $3.6 billion in Europe and $8.5 billion in the United States, with a global market of approximately $16 billion. Off-label repackaged bevacizumab (Avastin) is widely used as a first-line treatment for wet AMD in both Europe (2.8 million injections annually) and the US (2.7 million injections annually), despite risks of contamination and inconsistent potency. Outlook Therapeutics' ONS-5010/LYTENAVA is positioned as the first and only authorized ophthalmic formulation of bevacizumab in the EU and UK, aiming to provide a safer, on-label, and affordable alternative to both off-label Avastin and higher-cost branded anti-VEGF therapies like Lucentis, Eylea, Beovu, and Vabysmo, as well as their biosimilars. The industry is highly competitive, with major pharmaceutical companies and emerging biotechs developing new treatments, including gene therapies and other novel mechanisms. Global healthcare trends emphasize cost-containment, with increasing scrutiny on drug pricing and reimbursement policies, which could impact market access and profitability for new therapies.

Comparison to Industry Standards

• ONS-5010/LYTENAVA is compared to ranibizumab (LUCENTIS) in clinical trials for wet AMD.
• In the pivotal Phase 3 NORSE TWO trial, ONS-5010/LYTENAVA demonstrated superior efficacy, with 41.7% of patients gaining at least 15 letters in BCVA score compared to 23.1% for ranibizumab (p = 0.0052). The mean change in BCVA was 11.2 letters for ONS-5010/LYTENAVA versus 5.8 letters for ranibizumab (p = 0.0035).
• In the NORSE EIGHT trial, ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 against ranibizumab (difference of -2.257 BCVA letters, 95% CI: -4.044, -0.470, with a non-inferiority margin of -3.5). However, at week 12, the non-inferiority margin was met (difference of -1.009 BCVA letters, 95% CI: (-2.865, 0.848)).
• The safety profile of ONS-5010/LYTENAVA across NORSE ONE, TWO, THREE, and EIGHT trials is consistent and favorable, with no cases of retinal vasculitis reported in any study arm.
• The company aims to strategically price ONS-5010/LYTENAVA as a lower-cost alternative to existing branded anti-VEGF therapies (e.g., LUCENTIS, EYLEA, BEOVU, VABYSMO) and their biosimilar versions (e.g., BYOOVIZ, CIMERLI, PAVBLU), while remaining above off-label compounded bevacizumab (Avastin).

Management Changes

Corporate Governance

Legal Proceedings

• A securities class action lawsuit was filed on November 3, 2023, in the United States District Court for the District of New Jersey against the company and certain officers. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5, claiming false and misleading statements related to the BLA for ONS-5010/LYTENAVA (lack of evidence, deficient CMC controls). Plaintiffs seek damages, interest, and legal costs. The defendants' motion to dismiss is pending.
• A shareholder derivative action was filed on October 10, 2024, in the District Court of the District of Delaware against certain current and former officers and directors. This complaint alleges breaches of fiduciary duties and violations of Section 14(a) of the Exchange Act, based on similar alleged misstatements as the class action, and also includes claims for contribution, unjust enrichment, and waste of corporate assets. It seeks unspecified damages, corporate governance reforms, restitution, contribution, and legal costs. This action is currently stayed pending the resolution of the securities class action.
• The company cannot estimate the possible cost of these matters, which could be material, and has not established any reserve for potential liability.

Related Party Transactions

• GMS Ventures and Investments (GMS) beneficially owned approximately 41.9% of the company's common stock as of September 30, 2025, and has the right to designate members to the board of directors.
• GMS purchased 2,305,714 shares of common stock and warrants to purchase 3,458,571 shares in a private placement that closed in March 2024.
• GMS purchased 4,285,714 shares of common stock and warrants to purchase 8,571,428 shares in the underwritten public offering completed in May 2025.
• Syntone Ventures LLC (Syntone) participated in a private placement that closed in April 2024, purchasing 714,286 shares of common stock and warrants to purchase 1,071,429 shares.
• The company entered into a joint venture agreement with Syntone's PRC-based affiliate, forming Beijing Syntone Biopharma Ltd (Syntone JV), which is 80% owned by Syntone PRC and 20% by Outlook Therapeutics. Outlook Therapeutics made an initial investment of $900,000 and is committed to making additional capital contributions of approximately $2.1 million.
• Syntone also agreed to exercise existing warrants for 1,071,429 shares of common stock in a Warrant Inducement Transaction in January 2025, subject to regulatory approval, for which the company agreed to issue two new inducement warrants for each exercised warrant.

Stakeholder Impact

• Shareholders face significant dilution risks from ongoing and future equity financing activities, including ATM sales, public offerings, and convertible debt conversions. The substantial doubt about the company's going concern status and the pending securities litigation pose material risks to investment value.
• Employees have been impacted by workforce reductions in December 2024 and September 2025, leading to severance costs and potential loss of institutional knowledge. The company's ability to attract and retain qualified personnel is critical for future development.
• Customers, including physicians and patients, may benefit from ONS-5010/LYTENAVA as a potentially safer, on-label, and affordable alternative to off-label bevacizumab for wet AMD, if US approval is obtained. However, market acceptance and reimbursement levels will be crucial.
• Creditors, particularly Avondale Capital, LLC, holding the March 2025 Note, are subject to quarterly debt reduction obligations and potential acceleration of debt with higher interest rates upon an Event of Default.
• Third-party partners and suppliers, such as Cencora for commercialization support and FujiFilm Diosynth Biotechnologies and PCI San Diego, Inc. for manufacturing, are critical to the company's operations. Disruptions or failures in these relationships could severely impact business.

Next Steps

• Await FDA decision on the resubmitted BLA for ONS-5010/LYTENAVA for wet AMD by the PDUFA goal date of December 31, 2025.
• Prepare for potential direct launch of ONS-5010/LYTENAVA in the United States if FDA approval is received.
• Investigate additional countries for direct commercialization or third-party partnerships for ONS-5010/LYTENAVA.
• Seek a variation to the current EU/UK marketing authorization to permit approval of ONS-5010/LYTENAVA supply in pre-filled syringes.
• Initiate NORSE FOUR, FIVE, and SIX clinical trials for BRVO and DME, pending initial FDA approval for wet AMD.
• Continue to pursue discussions with additional potential strategic partners for ONS-5010/LYTENAVA outside of the United States.
• Complete the Syntone Warrant Inducement Transaction, subject to regulatory approval, to receive approximately $2.4 million in proceeds.
• Repay at least $3.0 million of the outstanding balance on the March 2025 Note each calendar quarter.
• Expect the majority of cash payments related to the September 2025 workforce reduction to be substantially complete by the third calendar quarter of 2026.
• Evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Disaggregation of Income Statement Expenses) on consolidated financial statements and disclosures.
• File the definitive proxy statement for the next Annual Meeting of the Stockholders no later than January 28, 2026.

Key Dates

Recommendation

Outlook Therapeutics faces critical challenges that warrant a strong sell recommendation. The company explicitly states "substantial doubt about our ability to continue as a going concern," indicating severe financial instability. The second Complete Response Letter from the FDA for ONS-5010/LYTENAVA, citing a lack of substantial evidence of effectiveness, is a major blow to its most promising product's entry into the lucrative US market. The NORSE EIGHT trial, intended to address FDA concerns, failed its primary endpoint at week 8, further complicating the regulatory path. While EU/UK approval and initial revenue are positive, they are insufficient to offset the significant financial and regulatory hurdles. The ongoing securities class action and derivative lawsuits add further legal and financial uncertainty. The need for substantial additional capital, coupled with significant dilution risks and a highly competitive market, presents an extremely high-risk investment profile with a strong negative outlook.

Keywords

Outlook Therapeutics, ONS-5010/LYTENAVA, wet AMD, bevacizumab, anti-VEGF, ophthalmology, FDA approval, EMA approval, MHRA approval, clinical trials, NORSE EIGHT, NORSE TWO, regulatory exclusivity, capital raise, going concern, securities litigation, corporate governance, intellectual property, biopharmaceutical, drug development, retinal diseases, DME, BRVO, Avastin, off-label use, pharmaceutical market